CAI•Caris Life Sciences said enrollment began in a study comparing ChromoSeq with conventional testing for myeloid cancers. The study plans to enroll about 300 adults at multiple U.S. institutions through July 2027.
The first patients enrolled in late September 2026 in a study testing ChromoSeq as an alternative to conventional testing for myeloid malignancies. About 300 adults are expected to enroll across multiple U.S. institutions through July 2027.
The study will prospectively compare the sequencing workflow with conventional testing for risk classification, ease of use and turnaround time. ChromoSeq combines whole-genome and whole-transcriptome sequencing in one report. Enrollment follows MolDX approval.
